Stirnadel-Farrant HA, Xu X, Kwiatek J, Jain P, Meyers J, Candrilli S, Mines D, Datto CJ. Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: a retrospective analysis of US health insurance claims data. JAAD Int. 2023 Jun 9;13:117-25. doi: 10.1016/j.jdin.2023.04.014
Lucas A, Sinha A, Fowler KB, Mladsi D, Barnett C, Samant S, Gibson L. A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States. Cost Eff Resour Alloc. 2019 Oct 3;17(1):21. doi: 10.1186/s12962-019-0189-0
Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019 Aug;44(4):495-507. doi: 10.1111/jcpt.12830
Goyal RK, Rajan SS, Essien EJ, Sansgiry SS. Effectiveness of FDA's new over-the-counter acetaminophen label warning requirements in improving consumer risk perception of liver damage. J Clin Pharm Ther. 2012 Dec;37(6):681-5. doi: 10.1111/j.1365-2710.2012.01371.x.
Zimovetz EA, Wolowacz SE, Classi PM, Birt J. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost Eff Resour Alloc. 2012 Feb 1;10(1):1.